Immunovaccine Inc.

Immunovaccine Inc.

September 09, 2010 13:00 ET

Immunovaccine to Present at the Rodman & Renshaw 12th Annual Healthcare Conference

HALIFAX, NOVA SCOTIA--(Marketwire - Sept. 9, 2010) - Immunovaccine Inc. (TSX VENTURE:IMV) announced the Company will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference on September 15, 2010 at 11:40 a.m. EDT at The Palace Hotel in New York City. Dr. Randal Chase, Immunovaccine's President and CEO, will discuss the Company's strategy, recent business development activities and its clinical research programs.

The conference will include a series of one-on-one meetings with investors and research analysts. Investors interested in scheduling a meeting with Immunovaccine, can facilitate a request by contacting the Company at or alternatively contact their Rodman & Renshaw representative.

Immunovaccine will also attend the BioPharm America 2010 Conference in Boston between September 15th and 17th, and the Company's director of business development, Vicki Morgan is available for partnering meetings during this time.

Immunovaccine Inc. (TSX VENTURE:IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information